Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8316339rdf:typepubmed:Citationlld:pubmed
pubmed-article:8316339lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0018026lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0036140lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C1519021lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0023866lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:8316339lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:8316339pubmed:issue5lld:pubmed
pubmed-article:8316339pubmed:dateCreated1993-7-26lld:pubmed
pubmed-article:8316339pubmed:abstractTextThe present study concerns the controversial subject of rheumatoid arthritis (RA) therapy and particularly use of orally administered gold salts (auric triethylphosphine-Auranofin). It contains the results of a study conducted on 10 patients affected with RA who were treated with auric triethylphosphine associated with conventional therapy for a period varying from 4 to 8 years. The efficacy of this therapy in these patients was comparable to that observed in a survey of other studies. The authors conclude that there are advantages offered to RA patients utilizing chrysotherapy and particularly Auranofin can be administered for an extended period without the development of collateral effects in other organs or systems.lld:pubmed
pubmed-article:8316339pubmed:languageitalld:pubmed
pubmed-article:8316339pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8316339pubmed:citationSubsetIMlld:pubmed
pubmed-article:8316339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8316339pubmed:statusMEDLINElld:pubmed
pubmed-article:8316339pubmed:monthMaylld:pubmed
pubmed-article:8316339pubmed:issn0026-4806lld:pubmed
pubmed-article:8316339pubmed:authorpubmed-author:MartinelliMMlld:pubmed
pubmed-article:8316339pubmed:authorpubmed-author:CordioliEElld:pubmed
pubmed-article:8316339pubmed:authorpubmed-author:CopertariNNlld:pubmed
pubmed-article:8316339pubmed:issnTypePrintlld:pubmed
pubmed-article:8316339pubmed:volume84lld:pubmed
pubmed-article:8316339pubmed:ownerNLMlld:pubmed
pubmed-article:8316339pubmed:authorsCompleteYlld:pubmed
pubmed-article:8316339pubmed:pagination219-25lld:pubmed
pubmed-article:8316339pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:meshHeadingpubmed-meshheading:8316339-...lld:pubmed
pubmed-article:8316339pubmed:year1993lld:pubmed
pubmed-article:8316339pubmed:articleTitle[Long-term therapy with gold salts in rheumatoid arthritis. Review of the literature and personal contribution].lld:pubmed
pubmed-article:8316339pubmed:affiliationIstituto di Patologia Speciale Medica e Metodologia Clinica, Università degli Studi di Bologna.lld:pubmed
pubmed-article:8316339pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8316339pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8316339pubmed:publicationTypeReviewlld:pubmed